Cis-platinum therapy of previously treated head and neck cancer: the Southwest Oncology Group's two-dose-per-month outpatient regimen.
Cis-platinum therapy of previously treated head and neck cancer: the Southwest Oncology Group's two-dose-per-month outpatient regimen.
复制标题
先前治疗过的头颈癌的顺铂疗法：西南肿瘤学组的每月两剂门诊治疗方案。
DOI：
10.1002/mpo.2950080303
复制
发表时间：
1980
期刊：
影响因子：
--
通讯作者：
McCracken,JD
中科院分区：
文献类型：
--
作者：
Panettiere,FJ;Lehane,D;Fletcher,WS;Stephens,R;Rivkin,S;McCracken,JD
西南肿瘤组在头颈癌患者中测试了一种门诊顺铂方案。疗程由两次剂量组成，间隔一周，计划每4周给药一次。89例低风险头颈癌患者接受了广泛的手术、放疗和/或多种药物治疗。16例（全部入组患者的18%和65例完全可评估患者的25%）有客观肿瘤消退。中位反应持续时间为136天。毒性为中度。骨髓抑制是最小的，只有3%的患者表现出白细胞最低点低于2000，不到2%的患者血小板计数低于50,000。8%的患者出现明显但可逆的肾功能损害。个体对此类肾毒性的易感性似乎是可以预测的。这种简单的门诊方案对低风险患者有效且毒性最小，值得进一步利用。
The Southwest Oncology Group tested an outpatient Cis‐platinum regimen in patients with carcinoma of the head and neck. Courses which consisted to two doses, a week apart, were scheduled to be given at 4‐week intervals. Eighty‐nine poor risk head and neck cancer patients, who had received extensive prior therapy with surgery, radiation, and/or multiple drugs were studied. Sixteen (18% of all entered and 25% of the 65 fully evaluable) had objective tumor regression. The median duration of response was 136 days. Toxicity was moderate. Myelosuppression was minimal with only 3% of patients exhibiting leukocyte nadirs below 2,000 and less than 2% experiencing platelet counts below 50,000. Significant, but reversible, impairment of renal function occurred in 8% of patients. Individual susceptibility to such renal toxicity appears to have been predictable. This simple outpatient program with its effectiveness and minimal toxicity in poor risk patients deserves further utilization.